Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice

W. M. Shannon, G. Arnett, F. M. Schabel, T. W. North, S. S. Cohen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.

Original languageEnglish (US)
Pages (from-to)598-603
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume18
Issue number4
StatePublished - 1980
Externally publishedYes

Fingerprint

Vidarabine
Herpesviridae Infections
Human Herpesvirus 1
Antiviral Agents
Adenosine Deaminase Inhibitors
Virus Diseases
Cell Culture Techniques
9-(2-hydroxy-3-nonyl)adenine

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice. / Shannon, W. M.; Arnett, G.; Schabel, F. M.; North, T. W.; Cohen, S. S.

In: Antimicrobial Agents and Chemotherapy, Vol. 18, No. 4, 1980, p. 598-603.

Research output: Contribution to journalArticle

@article{6b2db8e405e54b29bfd71e8e25308f06,
title = "Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice",
abstract = "Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.",
author = "Shannon, {W. M.} and G. Arnett and Schabel, {F. M.} and North, {T. W.} and Cohen, {S. S.}",
year = "1980",
language = "English (US)",
volume = "18",
pages = "598--603",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice

AU - Shannon, W. M.

AU - Arnett, G.

AU - Schabel, F. M.

AU - North, T. W.

AU - Cohen, S. S.

PY - 1980

Y1 - 1980

N2 - Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.

AB - Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.

UR - http://www.scopus.com/inward/record.url?scp=0019163980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019163980&partnerID=8YFLogxK

M3 - Article

C2 - 6255863

AN - SCOPUS:0019163980

VL - 18

SP - 598

EP - 603

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -